Status:
COMPLETED
Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Pituitary Tumors
Eligibility:
All Genders
18-85 years
Brief Summary
Recent studies estimate that the prevalence of pituitary adenomas is approximately 1/1500 persons. Pituitary tumours are usually considered as benign. However, local invasion is reported in 35-40% of ...
Eligibility Criteria
Inclusion
- Only patient with complete clinical, radiological and hormonal data available during yearly follow-up will be included.
- Preoperative MRI will be used to classify the tumour as invasive, and postoperative MRI will be collected to confirm recurrence or progression of the tumour.
- Presence of tumour fragments fixed in Holland-Bouin's fluid or Neutral Buffered Formalin fixative available for aCGH analysis.
Exclusion
- Patient who underwent systematic post-operative radiotherapy.
- Patient presenting Multiple Endocrine Neoplasia type 1 (MEN1) or aryl hydrocarbon receptor interacting protein (AIP) mutation since mechanism of tumorigenesis are different to sporadic pituitary tumours.
Key Trial Info
Start Date :
September 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT01903967
Start Date
September 1 2013
End Date
January 1 2017
Last Update
January 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon - Groupement Hospitalier Est
Lyon, France, 69003